Silence Therapeutics PLC

$2.82
(as of Mar 31, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Silence Therapeutics PLC

Stock Price
$2.82
Ticker Symbol
SLN
Exchange
NASDAQ

Industry Information for Silence Therapeutics PLC

Sector
Healthcare
Industry
Biotechnology

Company Description for Silence Therapeutics PLC

Website
https://www.silence-therapeutics.com
Country
USA
Full Time Employees
116

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Fundamentals for Silence Therapeutics PLC

Market Capitalization
$222,853,840
EBITDA
$-58,006,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-1.70
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
47,214,800
Percent Owned by Insiders
13.73%
Percent Owned by Institutions
55.57%
52-Week High
52-Week Low

Technical Indicators for Silence Therapeutics PLC

50-Day Moving Average
200-Day Moving Average
RSI
34.83
ATR
0.38

Analyst Ratings for Silence Therapeutics PLC

Strong Buy
3
Buy
3
Hold
0
Sell
0
Strong Sell
0

News About Silence Therapeutics PLC

Aug 7, 2024, 9:00 AM EST
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. See more.
Jul 25, 2024, 6:08 AM EST
Wall Street likes to peer into the fog of the future and guess where a stock is headed. See more.
Apr 11, 2024, 12:24 PM EST
Biotech stocks can offer some of the most explosive, exciting opportunities on the market. See more.
Mar 18, 2024, 8:01 PM EST
Why do you want to consider biotech stocks? See more.